Glatiramer acetate

Evidence-based neurology checklist on glatiramer acetate: Mode of action Glatiramer acetate competes with myelin basic protein (MBP) It blocks the myelin damage caused by B cells Dosing Dermatological side effects Other side effects Monitoring Acronym

Mode of action

  • Glatiramer acetate competes with myelin basic protein (MBP)
  • It blocks the myelin damage caused by B cells

Dosing

Dermatological side effects

Other side effects

Monitoring

Acronym

References

  1. Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis – a review of approved medications. Eur J Neurol 2016; 23(Suppl 1):18-27.
  2. Rice CM. Disease modification in multiple sclerosis: an update. Pract Neurol 2014; 14:6-13.
  3. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45:1268-1276.
  4. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1503-1511.
  5. Dargahi N, Katsara M, Tselios T, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci 2017; 7(7) pii: E78. 
  6. And 4 more. Subscribe to see the full list

Related checklists

Loading...